Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
4 studies found for:    21220472 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)
Condition: Metastatic Non-squamous Non Small Cell Lung Cancer
Interventions: Drug: CBP501 + Cisplatin + Pemetrexed;   Drug: Cisplatin + Pemetrexed
2 Completed Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Conditions: Malignant Pleural Mesothelioma;   Solid Tumors
Interventions: Drug: pemetrexed, cisplatin and CBP501;   Drug: pemetrexed and cisplatin
3 Completed Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
Conditions: Cancer;   Solid Tumors
Intervention: Drug: CBP501 and Cisplatin
4 Not yet recruiting CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors
Condition: Advanced Solid Tumors
Intervention: Drug: CBP501

Study has passed its completion date and status has not been verified in more than two years.